Literature DB >> 15288280

Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?

Jian-Ming Xu, Angelo Paradiso, Howard L McLeod.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15288280     DOI： 10.1016/j.ejca.2004.04.028

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.

Authors:  Jian Ming Xu; Yu Han; Yue Min Li; Chuan Hua Zhao; Yan Wang; Angelo Paradiso
Journal:  BMC Cancer       Date:  2006-12-16       Impact factor: 4.430

2.  Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.

Authors:  Elli Narvi; Katri Vaparanta; Anna Karrila; Deepankar Chakroborty; Sakari Knuutila; Arto Pulliainen; Maria Sundvall; Klaus Elenius
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

3.  Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.

Authors:  Amalia Azzariti; Letizia Porcelli; Jian-Ming Xu; Grazia Maria Simone; Angelo Paradiso
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.